Welcome to the new home of BOPA!

The British Oncology Pharmacy Association (BOPA) is pleased to announce the re-launch of its website, bopawebsite.org. The completely redesigned website provides a modern user-friendly navigation compatible with mobile devices, bringing BOPA’s previous e-Learning centreforums and association information offering under one roof.

Unveiling the new site on Friday during the Annual BOPA Symposium in Manchester, chair Helen Flint said, “The relaunch of BOPA’s website was based on feedback we obtained from our members who wanted a simpler and more intuitive experience. By creating this new platform we have now made it much easier for our members to interact with their peers, take our online training courses and access BOPA’s rich pool of resources in one place.”

Latest News

By BOPA Committee on 23rd May 2024

CAPhO IDEA Virtual Workshop Inclusion, Diversity, Equity and Access (IDEA) in Oncology Pharmacy Virtual Workshop

BOPA and CAPhO ongoing collaboration CAPhO will be hosting a virtual half-day workshop on IDEA (Inclusion, Diversity, Equity and Accessibility) in Oncology Pharmacy on Saturday, June 1st from 9am-2:30pm MDT…

Read article
By BOPA committee on 22nd May 2024

Podcast released: Let’s Talk About Research

In this episode we are joined by Pinkie Chambers. We discuss her current research project, the role of a pharmacist as a principal investigator and getting involved in research. This…

Read article
By BOPA EDI Subcommittee on 22nd May 2024

Join BOPA’s Celebrate Pride Month Webinar on 6th June 2024

To celebrate Pride Month, BOPA is collaborating with European Cancer Organisation to host a webinar on clinical considerations for the safe and effective prescribing for trans individuals living with cancer.…

Read article
By BOPA SACT Verification Passport Group on 22nd May 2024

BOPA SACT Verification Passport Grandparenting Reminder

Dear member,   It has been 7 months since the launch of the BOPA SACT Verification Passport. We have over 100 registered sites and over 1000 users subscribed. This is…

Read article